Global Blood Therapeutics Receivables

Global Blood Therapeutics (GBT) currently reports a receivables of $30M as of June 2022. That compares with $20M in the prior-year period — up 52.3% year over year. Use the charts on this page to explore Global Blood Therapeutics's receivables history and peer comparisons.

Global Blood Therapeutics's receivables increased from $20M to $30M — a 52.3% year-over-year increase (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Global Blood Therapeutics reported $30M in receivables as of June 2022. That compares with $20M in the prior-year period — up 52.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $30M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Global Blood Therapeutics, and consider following GBT for alerts when major investors trade the stock.

Global Blood Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $30M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GBT with unrelated industries.